healthcare reimbursement

How much governments and insurers pay for care, tests and drugs, and whether they cover them at all.

Exposure · 25 companies

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

  • ADRX ADARx Pharmaceuticals, Inc.

    Exposed“Payers can limit coverage, impose cost-sharing or favor cheaper alternatives.”

    Latest 424B4final IPO prospectusPositivePre-revenue ·

    Develops siRNA drugs for hereditary angioedema and other diseases; $446M all-primary raise funds clinical development

  • APMD Apnimed, Inc.

    Exposed“Our ability to successfully commercialize Oxnimbi or any future product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third-party payors, including government healthcare programs (e.g., Medicare, Medicaid), managed care providers, private health insurers, health maintenance organizations, and other organizations.”

    Latest 424B4final IPO prospectusBankruptcy / going concernAccounting issueCEO/CFO change ·

    Develops Oxnimbi, a once-nightly sleep apnea pill; $192M all-primary raise funds regulatory work and launch if approved.

  • ASPE Aspen Neuroscience, Inc.

    Exposed“Successful sales of our products in the U.S. market, if approved, will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs or private health insurance (including managed care plans).”

    Latest 424B4final IPO prospectusBankruptcy / going concernPre-revenue ·

    Develops patient-derived Parkinson’s cell therapy; $141M all-primary raise backs sasineprocel’s move toward Phase 3

  • ATTO Attovia Therapeutics, Inc.

    Exposed“Coverage and reimbursement are uncertain.”

    Latest 424B4final IPO prospectusPositivePre-revenue ·

    Develops immune-disease biologics using ATTOBODY; $289M all-primary raise backs clinical validation of itch treatment ATTO-1310.

  • BRVE Braveheart Bio, Inc.

    Exposed“Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations.”

    Latest 424B4final IPO prospectusPositiveImpairment / chargePre-revenueRelated-party dependence ·

    Develops BHB-1893, an oral cardiac myosin inhibitor for hypertrophic cardiomyopathy; $383M all-primary raise funds Phase 3 trials.

  • CAPR CAPRICOR THERAPEUTICS, INC.

    Exposed“Infusion logistics, treatment-center capacity, site-of-care requirements, safety and labeling, competition, reimbursement and physician and patient adoption could limit uptake even if the product is approved.”

    Latest 10-QQ3 FY2026NegativeRestructuring ·

    Deramiocel’s FDA bid narrows to upper-limb impairment after an adverse cardiac efficacy vote; a Nippon Shinyaku dispute complicates launch plans.

    • Revenue$0vs $0 year ago
    • Net income−$42.7MYoY −73.6%
  • CDNA CareDx, Inc

    Exposed“More broadly, coverage changes, audits, payer denials, inadequate private-payer rates and negative technology assessments could reduce reimbursement or utilization.”

    Latest 10-QQ3 FY2026Positive ·

    Naveris adds NavDx oncology testing as lab products exit; accelerating transplant demand and older-test revenue recognition fuel growth.

    • Revenue$139.4MYoY +39.3%
    • Net income$19.3Mvs $1.7M year ago
  • CVS CVS Health

    Exposed“Pharmacy & Consumer Wellness: Q3 revenue and operating income reflected regulatory-related drug price reductions, generic introductions and reimbursement pressure, partly offset by favorable drug mix, brand inflation, prescription volume and Rite Aid contributions.”

    Latest 10-QQ3 FY2026Mixed ·

    Planned split separates Aetna and Caremark from CVS Pharmacy as insurance profitability improves and pharmacy pricing pressure persists.

    • Revenue$108.4BYoY +5.4%
    • Net income$2.2Bvs −$4.0B year ago
  • DHR Danaher Corporation

    Exposed“China’s 9M weakness partly reflected healthcare pricing and reimbursement changes, although sales there returned to year-over-year growth in Q3.”

    Latest 8-KPositiveEarningsGuidance raised ·

    Improving end markets accelerated core growth outside respiratory testing; FY2026 adjusted EPS guidance rose to $8.57–$8.62.

  • ELV Elevance Health

    Exposed“Rate-setting lags and delayed premium approvals may leave government-program rates inadequate or delay revenue recognition.”

    Latest 8-KGuidance reaffirmed ·

    FY2026 outlook reaffirmed for investor meetings: EPS of at least $22.00 diluted and $29.00 adjusted.

  • EMI Encore Medical, Inc.

    Exposed“Adoption also depends on third-party reimbursement; coverage restrictions, reimbursement cuts, hospital purchasing practices, group purchasing negotiations, and competitor discounts may constrain demand and margins.”

    Latest S-1/Aamended IPO prospectusNegativeBankruptcy / going concernAccounting issueCustomer concentration ·

    Sells catheter-delivered devices to close holes in the heart; IPO triggers a $7M technology license outside its core business

  • HCA HCA Healthcare

    Exposed“Federal Budget Act and CMS restrictions on provider taxes and Medicaid supplemental or state-directed payments could reduce federal matching funds, pressure state budgets, and affect reimbursement or coverage; the timing and impact remain uncertain.”

    Latest 8-KDebt financing ·

    Completed a $6.5B senior notes offering through HCA Inc., backed by HCA Healthcare’s senior unsecured guarantee.

  • ISRG Intuitive Surgical

    Exposed“Because there is often no separate payment for the use of our products, the additional cost associated with the use of our products can affect the profit margin of the hospital or surgery center where the procedure is performed.”

    Latest 8-KLeadership change ·

    Humana insurance chief Aaron Martin appointed independent director, expanding the board effective Jan. 1, 2027.

  • LTGO Latigo Biotherapeutics, Inc.

    Exposed“Our ability to commercialize any products successfully will also depend in part on the extent to which coverage and adequate reimbursement for our drug candidates, if approved, will be available from government health administration authorities, private health insurers and other organizations.”

    Latest 424B4final IPO prospectusPositiveBankruptcy / going concernAccounting issuePre-revenue ·

    Develops oral Nav1.8 non-opioid pain drugs; $346M all-primary raise backs LTG-001 pivotal trials and LTG-321 chronic-pain studies.

  • MYGN Myriad Genetics

    Exposed“Presently, approximately 61% of our revenue comes from private third-party payors.”

    Latest 8-KExecutive pay ·

    One-time retention options for the CFO, COO and chief scientific officer support leadership continuity as Myriad works to improve efficiency.

  • NUOX NuvOx Therapeutics, Inc.

    Exposed“Pricing, reimbursement, formulary access, comparative efficacy, safety and convenience will affect demand.”

    Latest S-1/Aamended IPO prospectusNegativeBankruptcy / going concernRestatementAccounting issue ·

    Intravenous oxygen drug developer seeks $20M gross at IPO midpoint to advance NanO₂ trials, with glioblastoma results the next major test

  • RGNA Regenlab USA Inc.

    Exposed“Reimbursement is uncertain and pricing pressure may constrain demand, including through public-hospital bids.”

    Latest S-1/Aamended IPO prospectusMixedBankruptcy / going concernRestatementAccounting issue ·

    Sells platelet-rich plasma kits; founder Antonino Turzi retains 87.66% ownership after the offering.

  • RZRA Rezera Inc.

    Exposed“Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval.”

    Latest S-1/Aamended IPO prospectusBankruptcy / going concernAccounting issueCEO/CFO change ·

    Develops oral anti-inflammatory drugs; IPO funds a pivotal ruvonoflast trial in peripheral artery disease, its first test in these patients.

  • STA Starton Holdings, Inc.

    Exposed“The potential market for STAR-LLD may be smaller than estimated, and adoption depends on meaningful advantages over existing treatments, physician and patient acceptance, and adequate coverage and reimbursement.”

    Latest S-1/Aamended IPO prospectusNegativeBankruptcy / going concernAccounting issuePre-revenue ·

    Develops continuous-delivery lenalidomide for blood cancers; offering funds trials but further capital is needed to reach approval

  • UNH UnitedHealth Group

    Exposed“Medicare Advantage faces funding pressure: multiyear rate shortfalls remain below forward medical cost trends despite the 2027 Final Notice moving toward those trends, and risk-adjustment changes further reduce funding, particularly for members with significant health and social needs.”

    Latest 8-KLeadership change ·

    Former Children’s Hospital of Philadelphia CEO Madeline Bell joins the board, bringing patient-care and hospital leadership experience.

  • VOGX Vogenx, Inc.

    Exposed“Even approval may not yield meaningful sales: physician and patient adoption, coverage, reimbursement, pricing, and cost-effective supply are uncertain.”

    Latest 424B4final IPO prospectusPositiveBankruptcy / going concernRestatementAccounting issue ·

    Developing oral mizagliflozin for post-bariatric hypoglycemia; $81.3M gross raise funds Phase 2 trials.

  • VRTX Vertex Pharmaceuticals

    Exposed“The company also must advance and commercialize products, including povetacicept for IgAN, and secure adequate payer coverage, pricing, and reimbursement.”

    Latest 10-QQ3 FY2026Positive ·

    Crinetics adds an endocrine franchise, but deal costs and launch spending squeeze profit despite ALYFTREK-led sales growth.

    • Revenue$3.4BYoY +11.8%
    • Net income$653.6MYoY −39.6%
  • VVVV vVARDIS Holding AG

    Exposed“Reimbursement may be limited for minimally invasive treatments.”

    Latest 424B4final IPO prospectusDebt defaultAccounting issueCustomer concentration ·

    Sells Curodont drill-free treatments for early cavities; Abivardi founders retain 86.9% of votes after the offering

  • WELL Welltower

    Exposed“Other significant uncertainties include changes in healthcare regulation and reimbursement, government investigations, and operators’ ability to obtain affordable liability insurance;”

    Latest 8-K ·

    Registers up to ≈1.15M shares for potential Welltower OP redemptions, plus shares for Silver Quebec LP exchanges and Fellowship Grants.

  • WMT Walmart

    Exposed“Pharmacy and health-and-wellness results are exposed to reimbursement rates, payer mix, formularies, drug costs, generic substitution, PBM consolidation, online competition and government drug-pricing initiatives.”

    Latest 8-KPositiveEarningsGuidance raised ·

    Better Walmart U.S. merchandise mix and higher membership income lift profit; FY2027 adjusted EPS outlook raised to $2.84–$2.89

Feedback